计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T413712-100mg |
100mg |
期货 ![]() |
| |
| T413712-250mg |
250mg |
期货 ![]() |
| |
| T413712-1g |
1g |
期货 ![]() |
|
| 别名 | 他泽司他(EPZ-6438) |
|---|---|
| 英文别名 | HMS3653O07 | Tazemetostat [USAN:INN] | Tazemetostatum | BCP07409 | HMS3747A09 | SW220030-1 | 5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((2-hydroxy-4,6-dimethylpyridin-3-yl)methyl)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide | N-[(4,6-Dim |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Tazemetostat (EPZ-6438) |
| 生化机理 | Tazemetostat(EPZ-6438,E7438)是一种强效的选择性 EZH2 抑制剂,在无细胞实验中的Ki和 IC50 分别为 2.5 nM 和 11 nM,相对于 EZH1 的选择性为 35 倍,相对于其他 14 种 HMT 的选择性大于 4500 倍。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 泽斯特增强子 2 多聚酶抑制复合体 2 亚基抑制剂 |
| 产品介绍 |
Tazemetostat (EPZ-6438, E7438)是一种有效的,选择性EZH2抑制剂,无细胞试验中Ki 和 IC50分别为2.5 nM 和 11 nM,比作用于EZH1选择性高35倍,比作用于14种其他HMT选择性高4500多倍。 Information Tazemetostat (EPZ-6438) Tazemetostat (EPZ-6438, E7438) is a potent, and selective EZH2 inhibitor with K i and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs. Targets EZH2 (Cell-free assay) 2.5 nM(Ki) In vitro EPZ-6438 concentration-dependently reduces global H3K27Me3 levels in wild-type or SMARCB1 mutant cells, and induces strong antiproliferative effects with IC50 ranging from 32 nM to 1000 nM in SMARCB1-deleted MRT cell lines. EPZ-6438 induces gene expression of neuronal differentiation and cell cycle inhibition, while inhibtis expression of Hedgehog pathway genes, MYC and EZH2. The antiproliferative effect of EPZ-6438 is enhanced by either prednisolone or dexamethasone in several EZH2 mutant lymphoma cell lines. In vivo In SCID mice bearing s.c. G401 xenografts, EPZ-6438 induces tumor stasis during the administration period and produces a significant tumor growth delay with minimal effect on body weight. Cell Research(from reference) Cell lines:Mutant cell lines (G401, A204, G402, KYM-1), Wild type cell line (RD, 293, SJCRH30) Concentrations:~10 μM Incubation Time:7 days |
| 纯度 | ≥99% |
| ALogP | 3.506 |
|---|---|
| HBD Count | 2 |
| Rotatable Bond | 9 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771831 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide |
| INCHI | 1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40) |
| InChi Key | NSQSAUGJQHDYNO-UHFFFAOYSA-N |
| Smiles | CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5 |
| Isomeric SMILES | CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5 |
| PubChem CID | 66558664 |
| 分子量 | 572.74 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL warmed with 50ºC Water: bath (174.59 mM); Water: ˂1 mg/mL Ethanol: ˂1 mg/mL |
|---|---|
| DMSO(mg / mL) Max Solubility | 5 |
| DMSO(mM) Max Solubility | 8.729964731 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 572.700 g/mol |
| XLogP3 | 4.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 9 |
| 精确质量Exact Mass | 572.336 Da |
| 单同位素质量Monoisotopic Mass | 572.336 Da |
| 拓扑极表面积Topological Polar Surface Area | 83.100 Ų |
| 重原子数Heavy Atom Count | 42 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 992.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
¥532.72
| 1. Hornick JL, Dal Cin P, Fletcher CD. (2009) Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.. Am J Surg Pathol, 33 (4): (542-50). [PMID:19033866] |
| 2. Patil PA, Lombardo K, Sturtevant A, Mangray S, Yakirevich E. (2018) Loss of Expression of a Novel Chromatin Remodeler SMARCA1 in Soft Tissue Sarcoma.. J Cytol Histol, 9 (6): (524). [PMID:31093468] [10.4172/2157-7099.1000524] |